Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 716 - файл
.pdf
https://t.me/med1917
INDEX
https://t.me/med1917
Note: Locators in italic indicate gures and in bold tables.
abrasions 2, 3, 164
abscess 114, 115, 117
acute skin trauma: assessment 6–10, 8–9, 8;
decision‑making, clinical 10–11, 12; dening
1–2, 2; initial management 11; types 2–6, 3–6
adhesive gauze, secondary dressing 87, 129
adhesive strips/patches 66; advantages, dis‑
advantages 81; application 89; contrain‑
dications 69; design, composition 66, 67;
indications 68, 81; primary dressing 89, 134;
secondary dressing 68, 129; wear duration 86
adverse reactions 119–123, 120–121
alginates 70–71, 70, 71, 89, 93; advantages,
disadvantages 82; contraindications 71;
indications 71, 82; primary dressing 128;
secondary dressing 82; wear duration 86
allergic contact dermatitis 9, 119–120,
136–137
anaphylaxis 12, 119, 120, 122, 143
animal bite 118, 118
antibiotics 117, 118, 120
antiseptics 34, 41, 43, 43, 45, 117, 119, 120, 143
assessment, monitoring, reassessment 6–10,
8–9, 8, 11, 104–107, 106, 122; see also clinical
practice scenarios
autolytic debridement 51–52, 59; contraindica‑
tions 52; indications 52; procedures 52, 52
avulsions 2–3, 3, 164
171
172 Index
https://t.me/med1917
blisters 3–4, 4, 53, 54, 130, 139, 164–165
bullae 114, 120, 143
bunching 89, 91, 107, 130
CA‑MRSA 114, 117
carbuncle 114, 117
cellulitis 114, 116, 117, 120
Centers for Disease Control and Prevention 24
channels 73, 73, 86, 143
chemical burns 120
chemical debridement 58–59; contraindications
58; indications 58; procedures 59, 59
clean technique 24–25, 25, 26, 35, 144, 155, 157
cleaning 23–24, 143
cleansing 33–45; evidence44–45; goal, purposes
34; patient, wound, clinician factors 34–35
cleansing solutions 41–44; normal saline 42, 42,
44–45, 126–127; potable tap water 42, 44–45,
145; temperature 37, 38, 41, 43–44, 126, 127
cleansing techniques 35–41, 164–167; hydro‑
therapy 40–41; irrigation 35–37; scrubbing,
swabbing 39–40, 164–167; selection factors
34–35; showering 37, 44; supply and equip‑
ment 36
clinical practice scenarios 125–142; adhered
dressing removal for assessment 135; allergic
contact dermatitis, diagnosing and treatment
136–137; dehiscence137; delayed healing
process, risk factor assessment 134; dressing
removal, unauthorized, wound reassessment
and education 127; dressing selection and
transitions, lateral proximal thigh trauma,
dressing options 128–129; education and
adherence, wound care 133; erythematous
maceration, development and treatment 129;
eschar removal for assessment 132; medical
product shortage, improvisation 126–127;
MRSA transmission prevention 131; oc‑
clusive dressings choices for limited budgets
138–139, 139; plantar foot blister treatment
for aquatic activities 130; thenar eminence
open blister, management plan 139–141
closure: primary 84, 145; secondary 84, 105,
130, 138, 145
community‑associated methicillin‑resistant
Staphylococcus aureus (CA‑MRSA) 114, 117
conservative sharp debridement 53–54; contra‑
indications 53; indications 53; procedures
53–54, 54
contamination 144; assessment 7, 35; cleaning
and disinfection 23–24; cleansing 34, 35,
36, 39, 40, 41; debridement 55; dressings 65;
hand hygiene 16; PPE 23; sterile and clean
techniques 24–25; wound management pro‑
cedures 25–26; see also infection; infection
control
debridement 49–60; ecacy, clinical evi‑
dence59; goal, purposes 49–50; patient,
wound, clinician factors 50; supply and
equipment 51
debridement, surgical 145, 148
debridement techniques 51–59, 164–167;
autolytic 51–52, 52, 59; chemical 58–59, 59;
conservative sharp53–54, 54; hydrotherapy
57–58; irrigation 54–55; scrubbing 55–56,
55; wet‑to‑moist 57; wet‑to‑dry 56–57
decontaminated 16, 23, 144
dehiscence12, 79, 117, 122, 137, 144
denuded 7, 106, 144
dermal adhesives 70, 77–80, 78, 83, 86, 89,
92–93; advantages, disadvantages 83, 117,
120, 122; application 92–93; contraindica‑
tions 78–79; evidence, clinical 79–80; indica‑
tions 78, 83; primary dressing 78, 89; wear
duration 86
dermis 1–2, 2
desiccated 8, 34, 52, 144
devitalized 8, 53, 54, 144
disinfection 23–24, 26, 36, 144
dressing, selection and application 80–85; ap‑
plication and clinical pearls 93–97, 94–97;
application guidelines 85–93; dressing types
characteristics 81–83, 84–85; patient char‑
acteristics 85; wound characteristics 84; see
also clinical practice scenarios; dressings’ own
headings
dressing types 65–79; nonocclusive 65–70,
66, 67–69, 79–80, 86, 86–89, 87, 88 see also
nonocclusive dressings; occlusive 70, 70–79,
71–75, 77–78, 82–83, 86, 89, 91–93, 91–95,
95, 97 see also occlusive dressings; selection,
application 80, 81–83, 84–85
dressings 63–97; adverse reactions 120; appli‑
cation guidelines 85–93; evidence, clinical
79–80; functions 65; moist wound heal‑
ing 64; monitoring and reassessment 107;
removal, unintended 127; selection, appli‑
cation, usage duration 80–85, 86; types see
dressing types; individual dressings’ headings;
wound dressings 63–64
ecchymosis 7, 106, 144
eczematous 12, 144
Index 173
https://t.me/med1917
edematous 114, 144
education and adherence see under patient
epidermis 1, 2, 2, 3, 107, 114, 135
erysipelas 114
erythema 2, 9, 12, 106, 114, 116, 134, 136, 144
erythematous 12, 119–120, 129, 144
eschar 8, 9, 34, 57, 106, 132, 144
examination gloves 17–18, 22–23, 25
exothermic 77, 144
exotoxin 65, 144
exudate 7, 34–35, 64, 65, 68, 69, 144
lms 70, 71–74, 72–74, 89; advantages, disad‑
vantages 72, 73, 82, 89; application 72, 89, 93;
channels, bunching 73, 73, 89, 91; contrain‑
dications 73–74; design, composition 71–72;
evidence, clinical 79; indications 72–73, 82;
primary dressing 82, 93, 138, 139; secondary
dressing 73, 82, 89, 93, 128; wear duration
72, 86
ap/roof, necrotic 4, 8
uctuance117, 144
foams 70, 74–75, 74, 89; advantages, disad‑
vantages 82; application 89, 93; contrain‑
dications 75; design, composition 74–75;
foam donut pads 95, 97; indications 75, 82;
primary dressing 75, 89, 128; secondary
dressing 82; wear duration 86
folliculitis 106, 114, 115, 120
furuncle 114, 117
gloves 16, 23; examination gloves application
17–18, 25; sterile gloves application 19–21,
25; gloves removal 22–23
granulation tissue 8, 8, 25, 50, 54, 56, 58, 144
hand hygiene, infection control 16
hydrocolloids 70, 76–77, 77–78; advantages,
disadvantages 83; application 89, 93; con‑
traindications 77; design, composition 76;
evidence, clinical 79–80; indications 76–77,
83; primary dressings 76, 77, 89, 128, 129,
130, 134, 138, 140; as secondary dressing 77,
79, 80, 83, 89; wear duration 86
hydrogels 75–76, 75; advantages, disadvantages
83; application 89, 93, 95; contraindications
76; design, composition 75–76; indications
76, 83; primary dressing 75–76, 89, 130, 140;
secondary dressing 83, 85, 95, 97; wear dura‑
tion 86
hydrotherapy 40–41, 57–58; contraindications
41, 58; indications 41, 58; procedures 41, 58
immunocompromised 12, 25, 122, 144
impermeable dressings see occlusive dressings
impetigo 114, 116, 117
impregnated sterile gauze 66–69, 66, 67, 81, 86;
application 88; see also woven, nonwoven
and impregnated sterile gauze
inanimate 16, 144
incisions 4, 6, 11, 59, 79–80, 166
induration 117, 144
infection 113–119; causes 114, 117; clinical
features, infected wounds 117; prevention
118–119, 118; treatment 117; types 114,
115–116
infection control 15–24, 15–29; cleaning, dis‑
infection 23–24, 26, 143, 144; hand hygiene
16; personal protective equipment (PPE) 16,
17–23, 23; standard precautions 16
infectious 16, 23, 25, 144
irrigation 35–37, 54–55; cleansing 35–37; clini‑
cal application 164–167; contraindications
36, 55; debridement 54–55; indications 36,
54; procedures 36–37, 37, 55; splash back
36–37, 38–39, 55; wound irrigation 38
irritant contact dermatitis 119–120, 120
island dressing 66, 67
lacerations 4, 5
lymphadenopathy 114, 117, 144
lymphangitis 117, 144
maceration 7, 86, 106–107, 120, 121, 129, 144
mitotic activity 43, 144
monitoring and reassessment 11, 104–107, 110;
dressing 107; patient 104–105; periwound
tissue 106–107; wound bed 105–106, 106; see
also clinical practice scenarios
MRSA/CA‑MRSA 114, 117, 131
mucocutaneous junctions 79, 83, 144
mucosal surfaces 79, 83, 144
necrotic 4, 8, 50, 56, 57, 145
necrotizing fasciitis 114
neomycin 118–119, 136
nonadherent pads 66; advantages, disadvantag‑
es 81; application 86–87; contraindications
69; design, composition 66, 67–68; indica‑
tions 68, 81; primary dressing 66, 68, 81, 138,
139; secondary dressing 81; strike‑through
68, 68; wear duration 86
nonocclusive dressings 65–70, 79–80, 86–89,
88, 95, 97; nonadherent pads, adhesive
strips/patches 66, 67–68, 67–69, 81, 86, 87,
174 Index
https://t.me/med1917
95; wound closure strips 66, 69–70, 69, 79,
81, 84, 86, 89, 90–91; woven, nonwoven and
impregnated sterile gauze 66–69, 66, 67, 81,
86, 87, 88, 95; see also under their own
heading
nonpurulent 114, 117, 145
nonwoven and woven sterile gauze see woven,
nonwoven and impregnated sterile gauze
normal saline 42, 42, 44–45, 126–127
no‑touch technique 26, 145
occlusive dressings 70–79, 70; alginates 70–71,
70, 71, 82, 86, 89, 93; dermal adhesives 70,
77–80, 78, 83, 86, 89, 92–93; lms 70, 71–74,
72, 79, 82, 86, 89, 91, 93; foams 70, 74–75,
74, 82, 86, 89, 93; hydrocolloids 70, 76–77,
77–78, 83, 86, 89, 93; hydrogels 70, 75–76,
83, 86, 89, 93, 95; see also under their own
headings
patient: assessment 6–11, 8–9, 8, 34, 50; educa‑
tion and adherence107–110, 127, 133; moni‑
toring and reassessment 104–107, 106
patient, monitoring and reassessment 104–107
periwound tissue 2, 4, 106–107, 145
personal protective equipment (PPE) 16,
17–23, 23
potable tap water 7, 42, 44–45, 145
primary closure 84, 145
primary dressing 10–11, 68, 72–73, 139, 145;
adhesive gauze with 87, 129; adhesive strips
and patches 81, 89; alginates 71, 128; dermal
adhesives 78, 89; lms 72, 82, 93, 138, 139;
foams 75, 89, 128; hydrocolloids 76, 77, 83,
89, 128, 129, 130, 134, 138, 140; hydrogels
75–76, 83, 89, 130, 140; inspecting 68, 68,
107, 109; nonadherent pads 66, 68, 81, 138,
139; strike‑through 68, 68; thin prole 95;
usage 65; wound closure strips 69, 81, 89;
woven and nonwoven gauze 66–68, 69, 81,
86, 87, 129
pruritic 119, 145
pruritus 12, 145
punctures 4, 5, 167
purulent 105, 114, 117, 122, 145
reassessment and monitoring 11, 104–107, 110;
dressing 107; patient 104–105; periwound
tissue 106–107; wound bed 105–106, 106
referral criteria 6, 10, 11, 42, 104, 104, 105, 122
saline see normal saline
sanguineous drainage 105, 145
scrubbing 39–40, 55–56; clinical application
164–167; contraindications 40, 56; indica‑
tions 39, 55; procedures 40, 40, 55, 56
secondary closure 84, 105, 130, 138, 145
secondary dressing 10–11, 139, 145; adhesive
strips/patches 68, 129; alginates 82; changes
108–109, 137, 140–141; lms 73, 82, 89,
93, 128; foams 82; hydrocolloids 77, 79, 80,
83, 89, 140; hydrogels 83, 85; nonadherent
pads, adhesive strips/patches 81, 89, 139;
nonadhesive primary dressings 66, 68, 75,
76, 86–87, 93, 95; primary dressing leak‑
age, strike‑through 68, 68; usage 65; woven,
nonwoven and impregnated sterile gauze 66,
81, 87
semipermeable dressings see occlusive dressings
serosanguinous drainage 105, 145
serous drainage 105, 145
showering 37, 44, 45; contraindications 37;
eectiveness 44; indications 37, 126; proce‑
dures 37
skin layers 1–2, 2
slough 8, 8, 145
slough o 78, 145
splash back 23, 36–37, 38–39, 55, 145
standard precautions 16, 23, 26, 35, 51, 85,
131, 145
staphylococci bacteria 114, 117, 118–119
staples 28, 157, 158–160
stellate 7, 145
sterile gloves 19–21, 25
sterile technique 24, 25, 26, 145
sterilization 24, 145
streptococci bacteria 114, 117, 118–119
strike‑through 68, 68, 145
subcutaneous tissue 1–2, 2, 10, 114
supercial epidermis 2
supercial‑thickness wounds 2
surgical debridement 145, 148
suture 28, 148–155, 149–155, 156–157
swabbing 39–40; contraindications 40; indica‑
tions 39; procedures 40, 40
thin prole, primary dressing 95
tissue approximation 69, 71, 75, 76, 78–79,
81–83, 89, 137, 145
topical antiseptics 34, 41, 43, 43, 45
tunnel 36, 145
Index 175
https://t.me/med1917
universal precautions 16, 145
urticaria 120, 121, 145
urticarial 12, 120, 145
vesicles 12, 146
viable, nonviable tissue 8, 24, 34, 37, 38, 50, 53,
54, 140, 146
viable wound 49–50, 54, 132, 141
wet‑to‑dry debridement 56–57; contraindica‑
tions 56; indications 56; procedures 57
wet‑to‑moist debridement 57;
contraindications 57; indications 57;
procedures 57
wound bed tissue assessment 7–9, 8–9, 8
wound care 101; infographic 162
wound characteristics 34, 50, 84
wound closure 147–160, 28
wound closure strips 66, 69, 81, 84; advantages,
disadvantages 81; application 89, 90–91;
contraindications 70; evidence, clinical 79;
indications 69, 81; primary dressing 69, 89;
wear duration 86
wound management, supplies 26, 27–29
woven, nonwoven and impregnated sterile
gauze 66; application 68, 87, 88; contrain‑
dications 69; design, composition 66, 67;
indications 66, 81; primary dressing 66–67,
69, 81, 86, 87, 129; secondary dressing 66,
81, 87, 137, 139; strike‑through 68; wear
duration 86
wrinkling 89, 91, 107, 130
Соседние файлы в папке @xirurgi_2025